Apellis Pharmaceuticals, Inc. Share Price & Technical Analysis
APLS · $41.03 (0.00%)
Healthcare / Biotechnology
$41.03
0.00%
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy …
Price chart
Seasonality
May has 1 positive and 3 negative years (last 5 years shown)
0% return in May, -4% avg return in past 3 year May month.
85% return in 2026, 12% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -10% | -5% | 98% | 2% | 0% | – | – | – | – | – | – | – | 85% |
| 25 | -10% | -12% | -12% | -12% | -11% | 1% | 25% | 24% | -18% | -6% | 0% | 20% | -12% |
| 24 | 6% | -2% | -7% | -25% | -12% | -3% | 3% | 2% | -25% | -5% | 24% | -6% | -50% |
| 23 | 4% | 25% | 1% | 12% | 12% | 6% | -71% | 66% | -10% | 26% | 17% | 11% | 98% |
| 22 | -15% | 7% | 17% | -15% | -5% | 8% | 24% | 8% | 13% | -9% | -18% | 4% | 19% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Strong · Overbought
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. In addition, it conducts preclinical studies for APL-9099, a treatment targeting the neonatal Fc receptor, or FcRn, which has the potential to be a first-in-class gene editing treatment for future target indications with one-time dosing; and developing other programs with its proprietary in-house capabilities and under its Beam collaboration. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics, Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Waltham, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$5.25B
P/E ratio
38.36
52W high
$41.14
52W low
$16.10
Volume
5,58,03,365
Beta
-0.25
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Apellis Pharmaceuticals, Inc. share price today?
- Apellis Pharmaceuticals, Inc. (APLS) last traded around $41.03 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does APLS have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for APLS. Download the app for real-time alerts.
- How can I analyze Apellis Pharmaceuticals, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.